<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> plays a crucial role in <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and progression </plain></SENT>
<SENT sid="1" pm="."><plain>Low expression of <z:chebi fb="0" ids="25354">mineralocorticoid</z:chebi> receptor (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) in several <z:mp ids='MP_0002018'>malignant tumors</z:mp> correlates with disease recurrence and overall survival </plain></SENT>
<SENT sid="2" pm="."><plain>Previous studies have shown that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> expression is decreased in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Here we hypothesize that decreased <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> expression can contribute to <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and poor patient survival in colorectal <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In a cohort of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, we analyzed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> expression, its correlation with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microvascular density and its impact on survival </plain></SENT>
<SENT sid="5" pm="."><plain>Subsequently, we interrogated the role of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> in <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in an in vitro model, based on the <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell line HCT116, ingenierized to re-express a physiologically controlled <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, decreased <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> expression was associated with increased microvascular density and poor patient survival </plain></SENT>
<SENT sid="7" pm="."><plain>In pchMR transfected HCT116, <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> or natural serum steroids largely inhibited <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels of both VEGFA and its receptor 2/KDR </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> activation may significantly decrease <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> by directly inhibiting dysregulated VEGFA and <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced VEGFA <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> activation attenuates the expression of the VEGF receptor 2/KDR, possibly dampening the activation of a VEGFA/KDR dependent signaling pathway important for the survival of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells under hypoxic conditions </plain></SENT>
</text></document>